First-line treatment of EGFR-mutant NSCLC: Spoiled for choice?
نویسندگان
چکیده
منابع مشابه
First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
While the small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors erlotinib and gefitinib have modest clinical benefit in unselected patients with non-small cell lung cancer after platinum-based chemotherapy, an emerging and potentially more elegant strategy is to move these agents to the frontline setting for select patients. Those with somatic mutations in EGFR respo...
متن کاملSpoiled for choice?
The transition from a theory that turned out trivial to a consistent replacement need not proceed in terms of inconsistencies, which are negation gluts. Logics that tolerate gluts or gaps (or both) with respect to any logical symbol may serve as the lower limit for adaptive logics that assign a minimally abnormal consequence set to a given premise set. The same obtains for logics that tolerate ...
متن کاملAfatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer--Letter.
We read with great interest the article by Pirazzoli and colleagues on the ability of afatinib and cetuximab (AC) combination to delay resistance compared with afatinib alone (A) in a mouse model of EGFR-mutant lung adenocarcinoma (1). The main mechanism of resistance to AC in animals was the T790M mutation. It was detected in the same proportion than observed in human tumors that became resist...
متن کاملNext-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor (EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant non-small-cell lung cancer (NSCLC). First-generation EGFR TKIs, binding competitively and reversibly to the ATP-binding site of the EGFR tyrosine kinase domain, have resulted in a significant improvement in outcome for NSCLC ...
متن کاملThe Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis
BACKGROUND The combination of chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) currently has become the hotspot issue in the treatment of non-small lung cancer (NSCLC). This systematic review was conducted to compare the efficacy and safety of the synchronous combination of these two treatments with EGFR TKIs or chemotherapy alone in advanced NSCLC. M...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Research, Statistics, and Treatment
سال: 2019
ISSN: 2590-3233
DOI: 10.4103/crst.crst_83_19